Population frequencies of single nucleotide polymorphisms (SNPs) in immuno-modulatory genes

Human Heredity

Volumn 55, Issue 4, 2003, Pages 171-178

  Martin, A M ^a,b,c   Athanasiadis, G ^b,c   Greshock, J D ^b,c   Fisher, J ^b   Lux, M P ^b   Calzone, K ^c   Rebbeck, T R ^b   Weber, B L ^b,c,d  

^a PENNSYLVANIA HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BRB II/III   (United States)

Author keywords

African American; Allele frequencies; Caucasian; Cytokines; SNPs

Indexed keywords

CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOTOXIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MUTATION; POPULATION; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; CYTOKINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC;

EID: 0142156651     PISSN: 00015652     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073201     Document Type: Article

References (63)

1. Demeter J, Messer G, Ramisch S, Mee JB, di Giovine FS, Schmid M, Herrmann F, Porzsolt F: Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther 1996;2:239-242.
2. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, Messer G: Polymorphism of the tumour necrosis factor-alpha and lymphotox-in-alpha genes in chronic lymphocytic leukaemia. Brit J Haem 1997;97:107-112.
3. Hurme M, Lahdenpohja N, Santtila S: Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med 1998;30:469-473.
4. Knight JC, Kwiatkowski D: Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Proc Assoc Am Phys 1999;111:290-298.
5. Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K: Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tiss Antigens 1999;53:527-533.
6. George S, Turner D, Reynard M, Navarrete C, Rizvi I, Fernando ON, Powis SH, Moorhead JF, Varghese Z: Significance of cytokine gene polymorphism in renal transplantation. Transplant Proc 2001;33:483-484.
7. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson A: Recipient tumor necrosis factor-α and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999;94:3941-3946.
8. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
9. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, et al: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncar-riers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31(1):55-9. Available from http:// www.ncbi.nlm.nih.gov/htbin-post/ Entrez/que-ry?db=m&form=6&dopt=r&uid=11967536.
10. Martin AM, Weber BL: Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 2000;92:1126-1135.
11. Shields PG, Harris CC: Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000;18: 2309-2315.
12. Weber BL, Nathanson KL: Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer 2000;36:1193-1199.
13. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK: MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-773.
14. Rebbeck T, Wang Y, Kantoff PW, Krithivas K, Neuhausen S, Godwin AK, Daly MB, Narod SA, Brunet J-S, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M: Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001;61(14):5420-5424.
15. Hutchings A, Purcell WM, Benfield MR: Increased costimulatory responses in African-American kidney allograft recipients. Transplantation 2001;71:692-695.
16. Hutchings A, Guay-Woodford L, Thomas JM, Young CJ, Purcell WM, Pravica V, Perrey C, Hutchinson IV, Benfield MR: Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Ped Transpl 2002;6:69-77.
17. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2001;2:61-70.
18. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999;1: 3-19.
19. Garte S: The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998;19:1329-1332.
20. Weber W: Populations and genetic polymorphisms. Molecular Diagnosis 1999;4:299-307.
21. Duell E, Millikan R, Pittman G, Winkel S, Lunn R, Tse C, Eaton A, Mohrenweiser H, Newman B, Bell D: Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10: 217-222.
22. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins P, Daly A, Wrighton S, Hall S, Maurel P, Relling M, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
23. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR: p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Nat Cancer Inst 2002;94:681-690.
24. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF: Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58: 65-70.
25. Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, Lin DX, Tan W, Lyn-Cook BD, Hammons GJ, Kadlubar FF: Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Cau-casians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761-766.
26. Hutchings A, Purcell WM, Benfield MR: Peripheral blood antigen-presenting cells from African-Americans exhibit increased CD80 and CD86 expression. Clin Exp Immunol 1999;118:247-252.
27. Shevde LA, Joshi NN, Shinde SR, Nadkarni JJ: Studies on functional status of circulating lymphocytes in unaffected members from cancer families. Hum Immunol 1998;59:373-381.
28. Ganguly A, Rock MJ, Prockop DJ: Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes [published erratum appears in Proc Natl Acad Sci USA 1994;91:5217]. Proc Natl Acad Sci USA 1993;90:10325-10329.
29. Harper K, Balzano C, Rouvier E, Mattel M, Luciani M, Goldstein P: CTLA4 and CD28 activated lymphocyte moleculaes are closely related in both mouse and human as to sequence, message expression, gene structure and chromosomal location. J Immunol 1991;47:1037-1044.
30. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J: A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992;22:396-402.
31. Guasch JF, Bertina RM, Reitsma PH: Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 1996;8:598-602.
32. Denny P, Lord CJ, Hill NJ, Goy JV, Levy ER, Podolin PL, Peterson LB, Wicker LS, Todd JA, Lyons PA: Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes 1997;46:695-700.
33. Nolsoe RL, Kristiansen OP, Sangthongpitag K, Larsen ZM, Johannesen J, Karlsen AE, Pociot F, Nerup J, Verge CF, Mandrup-Poulsen T: Complete molecular scanning of the human Fas gene: mutational analysis and linkage studies in families with type I diabetes mellitus. The Danish Study Group of Diabetes in Childhood and The Danish IDDM Epidemiology and Genetics Group. Diabetologia 2000;43: 800-808.
34. D'Alfonso S, Richiardi PM: A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994;39:150-154.
35. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW: An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-560.
36. Tounas NA, Cominelli F: Identification and initial characterization of two polymorphisms in the human Il-10 promoter. Eur Cytokine Network 1996;7:578.
37. Olomolaiye OO, Wood NAP, Bidwell JL: Identification of a novel polymorphism in the IL-6 promoter region. Immunology 1997;92:66.
38. Messer G, Spengler U, Jung MC, Honold G, Eisenburg J, Scholz S, Albert ED, Pape GR, Riethmuller G, Weiss EH: Allelic variation in the TNF-beta gene does not explain the low TNF-beta response in patients with primary biliary cirrhosis. Scand J Immunol 1991;34(6): 735-740.
39. Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, Riethmuller G, Weiss EH: Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med. 1991;173:209-219.
40. Abraham L, Kroeger K: Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999;66:562-566.
41. Viola J, Rao A: Molecular regulation of cytokine gene expression during the immune response. J Clin Immunol 1999;19:98-108.
42. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on inter-leukin 6 transcriptional regulation. J Biol Chem 2000;275:18138-18144.
43. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376.
44. Morse H, Olomolaiye O, Wood N, Keen L, Bidwell J: Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 1999;11:789-795.
45. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-3199.
46. Pociot F, Wilson AG, Nerup J, Duff GW: No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:3050-3053.
47. Turner DM, Grant SC, Lamb WR, Brenchley PE, Dyer PA, Sinnott PJ, Hutchinson IV: A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 1995;60:1113-1117.
48. Sotgiu S, Pugliatti M, Serra C, Rosati G, Dolei A, Marrosu MG: Tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-alpha production in Sardinian multiple sclerosis. Ann Neurol 1999;46:799-800.
49. Maurer M, Kruse N, Giess R, Kyriallis K, Toyka KV, Rieckmann P: Gene polymorphism at position -308 of the tumor necrosis factor alpha promotor is not associated with disease progression in multiple sclerosis patients. J Neurol 1999;246:949-954.
50. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-3199.
51. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D: Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371: 508-510.
52. Tian H, Brody LC, Fan S, Huang Z, Landers JP: Capillary and microchip electrophoresis for rapid detection of known mutations by combining allele-specific DNA amplification with heteroduplex analysis. Clin Chem 2001;47: 173-185.
53. Gray IC, Campbell DA, Spurr NK: Single nucleotide polymorphisms as tools in human genetics. Hum Mol Genet 2000;9:2403-2408.
54. Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M: A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 1999;105:72-78.
55. Wagner TMU, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pages S, Sandberg T, Caux V, Moeslinger R, Langbauer G, Borg A, Oefner P: Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 1999;62:369-376.
56. Phillips J, Smith ED: Breast cancer control and African American women: a review. Cancer Invest 2001;19:273-280.
57. Rose DP, Royak-Schaler R: Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prevent 2001;25:16-31.
58. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J Nat Cancer Inst 2002;94:334-357.
59. Richardus JH, Kunst AE: Black-white differences in infectious disease mortality in the United States. Am J Public Health 2001;91: 1251-1253.
60. Chouchane L, Sfar I, Bousaffara R, El Kamel A, Sfar MT, Ismail A: A repeat polymorphism in interleukin-4 gene is highly associated with specific clinical phenotypes of asthma. Int Arch Allergy Immunol 1999;120:50-55.
61. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
62. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
63. den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet 2001;109:121-124; DOI 10.1007/s004390100505.